Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $484,845.47 in Stock

05 Mar 2026, 21:23 by Teresa Graham · The Cerbat Gem

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 30,941 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $15.67, for a total value of $484,845.47. Following the completion of the sale, the chief operating officer owned 583,911 shares in the company, valued at approximately $9,149,885.37. This represents a 5.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Julie Rubinstein also recently made the following trade(s):

On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.00, for a total value of $495,056.00.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ ADPT traded down $0.51 during midday trading on Thursday, hitting $15.93. 1,850,817 shares of the company’s stock were exchanged, compared to its average volume of 1,676,883. The firm’s fifty day simple moving average is $16.83 and its 200-day simple moving average is $15.79. The company has a market cap of $2.45 billion, a PE ratio of -39.82 and a beta of 2.19. Adaptive Biotechnologies Corporation has a twelve month low of $6.26 and a twelve month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last released its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company had revenue of $71.68 million for the quarter, compared to analysts’ expectations of $59.38 million. During the same quarter last year, the company earned ($0.23) earnings per share. The firm’s revenue for the quarter was up 51.0% on a year-over-year basis. Equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Adaptive Biotechnologies News Roundup

Here are the key news stories impacting Adaptive Biotechnologies this week:

Positive Sentiment: Q4 results and revenue beat — Adaptive reported stronger-than-expected Q4 results (EPS beat and revenue +51% YoY), which supports longer-term growth expectations and was a catalyst for bullish analyst notes earlier this quarter. MarketBeat ADPT page
Positive Sentiment: Analyst backdrop mostly constructive — Multiple firms have buy/overweight ratings and recent price-target increases (consensus “Moderate Buy”), which provides support vs. headline volatility. Analyst coverage summary
Neutral Sentiment: Short-interest data shows an anomalous 0-share reading and a 0.0 days-to-cover metric — this appears to be a data/reporting artifact rather than a meaningful change in bearish positioning. (No actionable signal until corrected data is posted.)
Neutral Sentiment: Small institutional activity — several modest new or increased stakes were reported in recent filings; institutional ownership remains high (~99%). These moves are small relative to market cap and unlikely to drive intraday price action. Institutional holdings
Negative Sentiment: Large CEO selling — CEO Chad Robins has executed multiple large sales, including a 289,024‑share sale on Mar. 2 at ~$15.82 (~$4.57M) and other recent disposals totaling hundreds of thousands of shares; these sizable reductions (one filing showed a ~12.7% position cut) are a near-term negative signal for investor sentiment. CEO sale SEC filing
Negative Sentiment: Other insider sales — COO Julie Rubinstein sold ~30.9k shares (filings show sales at ~$15.67–$16.00 for ~$485k–$495k), and director/insider Harlan Robins sold multiple blocks (10k and ~14.2k shares). Multiple insider sales in a short window amplify market concern about near-term insider conviction. COO sale SEC filing Harlan sale SEC filing

Institutional Trading of Adaptive Biotechnologies

Several hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd acquired a new position in shares of Adaptive Biotechnologies during the fourth quarter worth about $28,000. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Adaptive Biotechnologies in the 4th quarter worth about $51,000. Invesco Ltd. grew its stake in Adaptive Biotechnologies by 248.8% in the 4th quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock valued at $50,468,000 after acquiring an additional 2,216,595 shares during the last quarter. Corient Private Wealth LLC increased its holdings in Adaptive Biotechnologies by 3.4% during the 4th quarter. Corient Private Wealth LLC now owns 71,908 shares of the company’s stock valued at $1,168,000 after acquiring an additional 2,347 shares in the last quarter. Finally, Strive Financial Group LLC purchased a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at about $52,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on ADPT. BTIG Research raised their price target on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Wall Street Zen raised shares of Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a report on Sunday, February 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Morgan Stanley began coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They set an “equal weight” rating and a $21.00 price objective on the stock. Finally, Guggenheim upped their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a report on Monday, January 26th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $18.25.

Check Out Our Latest Analysis on Adaptive Biotechnologies

About Adaptive Biotechnologies

(Get Free Report)

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.